Abstract WMP54: Stroke Secondary Prevention Care In Persons With Schizophrenia

• Published in: Stroke (1970) 2022-02, Vol.53 (Suppl_1), p.AWMP54-AWMP54
• Main Authors: Matheson, Emilie N, Porter, Joan, Kurdyak, Paul, Yu, Amy Y, Fang, Jiming, Sheehan, Kathleen A, Casaubon, Leanne K, Kapral, Moira K
• Format: Article
• Language: English
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/str.53.suppl_1.WMP54

IntroductionSchizophrenia is associated with stroke incidence and case-fatality but the causes of this are not well-understood. We evaluated the association between comorbid schizophrenia and the quality of secondary prevention care after ischemic stroke. MethodsWe used linked health administrative data to identify adults discharged alive from acute care hospitals in Ontario, Canada between 2004 and 2017 following an incident ischemic stroke and identified those with a history of schizophrenia using a validated algorithm. Outcomes were screening, treatment among those with the risk factor, control of vascular risk factors, and receipt of outpatient physician services. We used modified Poisson regression to model the relative risk of each indicator outcome among persons with and without schizophrenia who were alive one year after discharge, adjusting for age, sex, income, comorbidity and rural residence. ResultsAmong 85,046 persons with ischemic stroke, 886 (1.04%) had a diagnosis of schizophrenia. Those with schizophrenia were younger (median age 64 vs 72), more likely to be female (50.1% vs 44.6%), live in the lowest neighbourhood income quintile (41.1% vs 23.0%) and have diabetes (42.8% vs 32.3%). Of those alive 1 year after stroke, those with schizophrenia were less likely to be screened for hyperlipidemia (adjusted relative risk (aRR) 0.89; 95% confidence interval (CI) 0.84 to 0.94) or diabetes (aRR 0.93; 95% CI 0.89 to 0.97), be prescribed antihypertensive agents (aRR 0.96; 95% CI 0.93 to 0.99), or achieve target lipid levels (LDL < 2 mml/L) (aRR 0.87; 95% CI 0.78 to 0.96). There were no differences in prescription of antilipemic (aRR 0.96; 95% CI 0.91 to 1.01) or antiglycemic (aRR 0.95; 95% CI 0.87 to 1.03) agents or in achievement of target HbA1c ≤ 7% (aRR 0.89; 95% CI 0.78 to 1.02). Outpatient stroke specialist care in the 3 months after discharge was less likely among those with schizophrenia (aRR 0.72; 95% CI 0.65 to 0.78) as were visits to primary care physicians (aRR 0.93; 95% CI 0.91 to 0.96). ConclusionsPeople with schizophrenia and stroke are less likely to receive secondary preventive care across many indicators measured. This information may be useful for targeted interventions to improve post-stroke care in those with schizophrenia.